CanBas Co., Ltd. (TYO:4575)
Japan · Delayed Price · Currency is JPY 859.00
-12.00 (-1.38%)
At close: Feb 6, 2026
CanBas Company Description
CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs.
It develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors.
CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
CanBas Co., Ltd.
| Country | Japan |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Takumi Kawabe |
Contact Details
Address: 2-2-1, Otemachi Numazu, 410-0801 Japan | |
| Phone | 81 55 954 3666 |
| Website | canbas.co.jp |
Stock Details
| Ticker Symbol | 4575 |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | July - June |
| Reporting Currency | JPY |
| ISIN Number | JP3244570002 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Takumi Kawabe | Chief Executive Officer |
| Makoto Katozumi | Chief Financial Officer |